New Directions in Treating Multiple Myeloma in the Era of Novel Agents

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Richter’s Syndrome: Risk, predictors, and treatmentПодробнее

Novel agents in myeloma: different targets and mechanisms of actionПодробнее

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее

Genetic profiling of multiple myeloma in the novel agents eraПодробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

The changing role of autoSCT in the treatment of multiple myeloma in the era of novel agentsПодробнее

The benefit of autologous transplantation in the era of novel agents in multiple myelomaПодробнее

A Doctor's Battle with Multiple MyelomaПодробнее

Dr. Richardson Discusses New Directions in Multiple MyelomaПодробнее

Challenges Seen With Novel Agents in Multiple MyelomaПодробнее

Integrating novel agents into the treatment of multiple myelomaПодробнее

The evolving treatment landscape in multiple myeloma & ongoing researchПодробнее

What are new treatment options for newly-diagnosed multiple myeloma patients? Dr. Paul G. RichardsonПодробнее

Multiple Myeloma: Novel Agents | Dana-Farber Cancer InstituteПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

Optimal Sequencing of Novel Agents in Relapsed/Refractory Multiple Myeloma ManagementПодробнее

Novel Agents for Multiple MyelomaПодробнее

A new era of treatment for multiple myelomaПодробнее

Introduction to novel treatmentsПодробнее